课题基金 / 基金详情

CA2 IN THE TREATMENT OF PATIENTS WITH ACTIVE CROHN'S DISEASE

CA2 IN THE TREATMENT OF PATIENTS WITH ACTIVE CROHN'S DISEASE
CA2 治疗活动性克罗恩病患者
批准号：
6244963
负责人：
KIM L ISAACS
金额：
$1.34万
依托单位：
UNIV OF NORTH CAROLINA CHAPEL HILL
依托单位国家：
美国
项目类别：
财政年份：
1997
资助国家：
美国
项目状态：
已结题
起止时间：
1997-01-06 至 1997-11-30
来源：
https://reporter.nih.gov/project-details/6244963
关键词：
Crohn's disease clinical research clinical trials dosage drug screening /evaluation gastrointestinal disorder chemotherapy human subject human therapy evaluation immunotherapy placebos tumor necrosis factor alpha

项目摘要

项目成果

KIM L ISAACS的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The purpose of this study is to evaluate the role of treatment of active Crohn's disease with a new drug (chimeric anti-TNF). The trial is a multi-center, placebo controlled tiral of 3 doses of anti-TNF and 1 dose of placebo in the treatment of active Crohn's Disease/100 patients who have active disease and who meet other entry criteria will be enrolled in approximately 15 center in the US and Europe.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
CLINICAL TRIAL: MULTI-SITE TRIAL OF AZATHIOPRINE DOSING IN CROHN'S DISEASE
MULTI-SITE TRIAL OF AZATHIOPRINE DOSING IN CROHN'S DISEASE
AZATHIOPRINE LOADING TO DECREASE RESPONSE TIME IN CROHN'S DISEASE
TAK 603/A 165646 IN PATIENTS W/ CROHNS DISEASE
海外基金